Last updated 01/07/2020
Primary care rebate schemes (PCRS) are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s).
The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.
Any decision to accept a PCRS is only made once a clinical decision to approve the use of a medication has been agreed locally.
We are unable to publish the full details of the PCRS because this information is commercially sensitive.
Although there are a number of PCRS available, NHS Salford CCG is currently signed up to the following:
| Companies involved | Drugs covered | Generic names | Start date | End date |
| Takeda UK Limited | Prostap | Leuprorelin acetate | Dec-15 | Open-ended |
| Fontus Health Limited |
Luventa XL, |
Galantamine, |
Mar-17 | Open-ended |
| Kyowa Kirin International plc | Adcal D3 | Calcium carbonate & colecalciferol | Apr-17 | Open-ended |
| Merck Serono Limited | Glucophage SR | Metformin | Apr-17 | Feb-21 |
| Ethypharm UK Ltd | Xaggitin XL |
Methlyphenidate |
Jun-20 | May-22 |
| Chiesi Ltd | Clenil Modulite | Belcometasone | Jul-20 | Jun-22 |
| ConvaTec Ltd | Dressings | N/A | Jul-20 | Jun-22 |
| Daiichi Sankyo UK Ltd | Lixiana | Edoxoban | Jul-20 | Dec-24 |
| Sanofi Aventis |
Apidra, Insuman |
Insulin glulisine, Isophane insulin |
Jul-20 | Jun-21 |